Browsing by Author "Soares, F"
Now showing 1 - 8 of 8
Results Per Page
Sort Options
- Association of anti-HBc seropositivity with undetectable or low level anti-HBs (<100) in anti-HCV positive blood donor population.Publication . Barradas, A; Barra, A; Baptista, F; Soares, F; Gaspar, R; Venâncio, B; Pereira, TIn this data we observed the association between confirmed. Anti-HCV positive and Anti-HBc positive with low level (<100) or undetectable Anti-HBs. b) ./. c) Between May 1995 to December 2001 we collected and analysed 24989 samples from volunteer blood donors. In this samples we performed the following tests Anti?HCV (Ortho), confirmed for PCR (Roche) or RIBA (Innogenetics), Anti-HBc (Dade-Behreing/Abbott, Anti-HBs (Abbott) and HCV genotype (Innogenetics). d) We found between Anti-HCV neg. population 6,94% positives Anti-HBc and 25,65% of them was Anti-HBs low level or undetectable. In the population we found 0,148% of confirmed Anti-HCV reactive donors, among them we found 51,35% of Anti-HBc positivity and between the last ones 78,9% had low level or undetectavel Anti-HBs. The ALT average level in the Anti-HCV positive donors was: Anti-HBc negative donors: 140,28 Ani-HBc positives with high level of Anti-HBs: 50,48 Anti-HBc positives with low or undetectable level of Anti-HBs: 64,11 e) The Anti-HCV confirmed donors associated to the Anti-HBc positives with low level or undetectable Anti-HBs (78,9%). Comparing with the Anti-HCV negative donors, positive for Anti?HBc and with low level or undetectable Anti-HBs (25,65%). This is statistically relevant.
- Casuistic of related blood donations incidents in HPFF Blood DepartmentPublication . Barra, A; Barradas, A; Gil, A; Costa, C; Silva, I; Rebelo, S; Simões, A; Rodrigues, T; Moura, H; Santos, L; Soares, FBackground Related blood donations incidents (RBDI) have to be reported to the Portuguese Haemovigilance Blood Group since de last year. In our department we have a manual system of incidents registration since 2006. We understand how is important the analysis of this data to prevent future incidents. Aims We want in some way to share our results aimed a better prevention of this incidents. Methods Data of RBDI between March of 2006 and December of 2009. This register include date, ID, age, sex, weight, time of incidents in relation to donation, donation status (first-time vs. repeat), type of incidents, the time window between last meal and donation. Measures to ease RBDI, past donor history and haemoglobin value before donation (g/dl). Results Between March of 2006 and December of 2009 we have registered 122 (0.60%) RDBI, in a total of 20067 allogeneic donations, 68.58% donations from men and 31.42% from women. RBDI were 70 in men (0.50% of male donations) and 52 in women (0.82% of female donations). The age of studied donors ranged between 19 and 62 ears old with an average of 32.21 ears (19-30 - 34.43%; 31-40 - 25,4%; 41-50 - 16,4%; 50-62 - 13,1%) . The average of weight was 70.1 Kilos. We found 96.2% of early RBDI (< 1h) and 3.8% were late (> 1h). RBDI was verified in 20 first time donors, 61 in donors who have donated less than 5 times and 41 in donors with more than 5 donations. What concern to past donor history 18 (14.75%) of blood donors that had RBDI tell us that they already have at least one BDI in past blood donations. We had to interrupted blood donation in 4 (3.27%) occasions. Hb average was 14.29 g/dl. In the first 6 months of the year RBDI are about half of those in the second semester. In most cases the RBDI happened within 10 minutes after initiation of blood donation and the last food intake occurred on average 1.5 hours prior to donation. Signs and symptoms. Most RBDI reversed with simple procedures (Trendelemburg donor position, drinking a sweet juice or water and heating of some biscuits). We didn’t find severe RDBI. Summary/conclusions In conclusion we can say that in our study most frequent RBDI were non-severe (vasovagal reaction), RBDI are few (~1/200 donations). RBDI were more frequent in young people. Early RBDI are more frequent than late. It seems that women are more likely to have BDI. We have not found a direct relationship between the level of Hb and RBDI. We found a relationship between the donations and the seasons, and in the warmer seasons there is a greater tendency to be RDBI. Probably in future we have to take steps to prevent RDBI.
- Cinco anos de experiência de TMA nos dadores de sangue do Hospital Amadora-SintraPublication . Soares, F; Gaspar, R; Rebelo, S; Barra, A; Barradas, AIntrodução: O risco de uma transfusão transmitir uma infecção a HIV, HIW e HVC é predominantemente associado a doações em que as infecções se encontram em estádios precoces e escapam aos outros testes de rotina. Assim em 2002 iniciamos o teste de Transcripção Mediada por Amplificação (TMA) aos nossos dadores diminuindo o período de janela das infecções referidas, aumentando a segurança transfusional. Material e Métodos: Foram testadas 26665 amostras no período compreendido entre Junho de 2002 a Dezembro de 2006. Inicialmente usamos o teste Chiron Procleix HCV/HIV tendo em 2004 passado para o Procleix Ultrio Assay HVC, HIV, HBV. Paralelamente efectuamos os testes Elisa segundo a lei portuguesa. Conclusão: O uso dos teste TMA em dadores singulares é fazível, aumenta a segurança transfusional detectando dadores em período de janela e não afecta o sangue disponível em stock.
- Detecção de Ag B19 numa população de dadores de sanguePublication . Barradas, A; Mercês, A; Barra, A; Baptista, F; Pereira, F; Santos, F; Soares, F; Pereira, TObjecto do estudo: Prevalência do Ag B19 numa população de dadores de sangue. Métodos utilizados: Entre Agosto e Dezembro de 2000 foram analisados no Serviço de Imuno-hemoterapia do Hospital Fernando da Fonseca 708 dadores para a detecção do Ag B19. O teste utilizado foi um teste de hemaglutinação em gel, utilizando células sensibilizadas, que na presença de partículas do B19 (contidas no soro/plasma do dador) aglutinam (ID-Parvovírus B19-DiaMed). Os dadores estudados tinham idades compreendidas entre os 18 e os 65 anos, sendo maioritariamente do sexo masculino, todos foram submetidos a consulta pré-dádiva e aprovados pelo médico. As amostras colhidas foram submetidas a controlo analítico para antigenémia do HBV, ac. anti-HBc, ac. Anti-HBs, ac.anti-HCV, ac. anti-CMV, ac. anti-HIV 1 e 2, VDRL, ALT (GPT) e PCR para o HCV. Resultados: Três dadores tiveram testes positivos para os AgB19 (0,424%), pertencendo todos ao sexo masculino e com idades compreendidas entre os 40 e os 49 anos, como marcadores concomitantemente positivos, havia um com acs. Positivos para o CMV, outro com GPT elevada e acs. anti-HBc, anti-HBs e anti-CMV positivos, o terceiro era negativo para todos os marcadores. Conclusões: Do nosso estudo não podemos concluir que exista uma correlação entre antigenémia positiva para o Parvovírus B19 e positiva para outros marcadores. Temos que, no futuro, avaliar da pertinência da execução deste teste em rotina de Banco de Sangue, aquando da transfusão de grávidas, recém-nascidos ou doentes imunodeprimidos.
- Prevalência de ac anti-CMV em dadores de sangue do Hospital Fernando Fonseca (2002-2006)Publication . Barra, A; Barradas, A; Costa, C; Monteiro, F; Soares, FO citomegalovírus (CMV) é um vírus pertence ao grupo dos herpes vírus e que tem como característica, a latência após a infecção primária, podendo reactivar-se posteriormente. O CMV tem sido referenciado como causa de aumento da morbilidade e mortalidade em recém-nascidos prematuros (pneumonia, hepatite, trombocitopenia). Outros dos receptores considerados de alto risco na infecção por CMV são, os doentes imunodeprimidos/imunossuprimidos e as grávidas. Nos Países com alta prevalência de CMV, a desleucocitação não é garante de não transmissão da infecção. Especialmente em prematuros, filhos de mães seronegativas, onde os componentes transfundidos, além de desleucocitados, devem ser CMV negativos.
- Prevalência de anti-CMV em dadores de sangue do Hospital Fernando Fonseca (1998-2002)Publication . Barra, A; Barradas, A; Monteiro, F; Soares, F; Pereira, TResumo: O citomegalovírus (CMV) pertence ao grupo dos herpes vírus contendo um DNA com duplo filamento, uma cápsula proteica, um involucro lipoproteico. Só ocorre naturalmente em seres humanos. Não sendo conhecido reservatório animal. Há três tipos de infecção primária: infecção secundária (outra estirpe); reactivação de vírus endógeno. Dado que o CMV tem sido referenciado como causa de aumento de morbilidade e de mortalidade em recém-nascidos prematuros, o Serviço de Imuno-hemoterapia do Hospital Fernando Fonseca tem feito, desde a sua abertura, o rastreio do anticorpo anti-CMV em todos os dadores de sangue. Os recém-nascidos, filhos de mães (IgG-CMV) positivas estão protegidos da infecção sintomática por CMV através de anticorpos adquiridos antes do nascimento. Contudo, o risco de infecção sintomática é maior nas crianças prematuras antes de terem recebido, transplancentariamente, quantidades de IgG anti-CMV materna. Estas crianças têm um risco acrescido para infecção por CMV, das quais se destacam a transmissão através das secreções cervicais das suas mães durante o parto (via neonatal); do leite materno (via pós-natal) ou de componentes sanguíneos infectados com CMV. Além dos prematuros, outros receptores considerados como sendo de alto risco de adquirirem infecção por CMV pós-transfusional estão os doentes imunodeprimidos/imunossuprimidos e grávidas.
- A retrospective study of B19 positive antigen blood donationsPublication . Mercês, A; Estevens, A; Barradas, A; Barra, A; Baptista, F; Soares, FBetween August and December 2000 using ID-Parvovirus B19 – DiaMed, we studied 708 blood donations to detect b19 Ag on the plasma kept in our serum colletion, we found a prevalence of 0,424% positive donations. Globoside, a P blood group antigen, is the major red blood cell receptor used by b19 for attachment and entry into the cell. This is why we have included it in our study. We performed the retrospective study in this blood components: Obtained results in blood donors (see poster). Obtained results of transfused patients with blood components from those donors (see poster). Conclusions: As it is possible to see in our results, one of the patients was infected recently by one blood unit. Our objective is not to transfuse this positive blood components to patients in risk, like individuals with underlying haemolytic disorders, immunocompromised patients, immunodeficient individuals, pregnant women, fetus and newborns. Other measures may be implemented, like: deferral permanently those donors, or researche P Ag in all patients?
- Transfusion therapy and sickle cell diseasePublication . Barra, A; Barradas, A; Cardoso, E; Costa, C; Ferreira, R; Fontes, A; Mota, M; Moura, H; Oliveira, C; Pereira, F; Rebelo, S; Rodrigues, T; Santos, L; Silva, A; Silva, I; Simões, A; Soares, F; Venâncio, BBackground: Sickle cell disease is a very common hemoglobinopathy. The main goal of transfusion therapy in sickle cell disease is to prevent thrombotic events, improve tissue oxygenation and treat anaemia complications. However the risk of all immunization is well known. Since 2001 our service has been doing a tight surveillance work in sickle cell patients, creating a database of about 15,000 studied blood donors. Aims: We want to share our experience in transfusion of sickle cell patients and highlight the importance to have a computer database with compatible donors in order to reduce all immunization in these patients. Methods: We have studied the above described donors for the following blood group systems ABO, Rh, Kell, Duffy, Kidd, MNSs, Lutheran, P (P1) and haemoglobin S. For each transfusion demand for these patients we research in our computer data base the more likely compatible donor. From January 2007 to January 2011 we studied 64 patients. To transfuse these patients we followed the protocol described above. We transfused these patients with red cells of compatible donors pre investigated. We perform pre transfusion tests in all patients. Results : Have been studied 64 patients who needed red cells transfusion, 30 were females and 34 were males. The range of ages was from 1 to 46 years old. 55 patients were black (85.9%). We have been able to transfuse these patients with red cells of 135 compatible donors from database. We performed 439 red cell concentrate (RCC) transfusions (average per patient 6.85). The patient with the biggest supply was transfused with 22 RCC and we didn’t find in this case any clinically significant red cell alloantibody. We had 7 positive antibody screenings, 2 were anti-Lea, 2 anti-E and 3 were inconclusive. Summary/Conclusions: In our study all patients with clinically significant alloantibody were previously transfused in other institution. We didn’t find any alloantibody in patients exclusively transfused in our department. Our experience transfusing sickle cell disease patients reveals that RCC compatible to antigens of the groups mentioned above greatly reduce all immunization. Hence the importance of the existence in urgency blood department of extended phenotype donors files.